Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease

Sheba Medical Center26 enrolled

Overview

The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery. The investigators also aim to study the short-term effect of bariatric surgery on gastric cholecystokinin levels before and 10 days after the bariatric surgery.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Nonalcoholic Fatty Liver Disease Nonalcoholic Steatohepatitis

Interventions

Sleeve gastrectomyPROCEDURE

An intra-operative liver biopsy was performed in 20 patients

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 20≤ age ≤80 * BMI\>35kg/m2 * Men and women * Fatty infiltration in liver ultrasonography Exclusion Criteria: * Alcohol drinking \> 140g/week * Presence of hepatitis B or C or HIV * Known liver disease such as: 1. Wilson's disease 2. hemochromatosis 3. α1-antitrypsin deficiency 4. autoimmune liver disease 5. primary biliary cirrhosis 6. primary sclerosing cholangitis)

Locations (1)

Liver Disease Center, Sheba Medical Center, Tel-Hashomer

Ramat Gan, Israel

Outcomes

Primary Outcomes

Change from baseline liver steatosis, steatohepatitis and fibrosis at different stages after bariatric surgery, measured by non-invasive measurements as described below.

Measurements to be performed to assess liver disease stage at baseline and at 8-12 days and 12, 24 and 48 weeks after surgery: 1. Blood tests of liver functions (Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase, gamma-glutamyl transpeptidase, ferritin, prothrombin-time (PT), international normalized ratio (INR), Total/Direct Bilirubin, Albumin, uric acid), lipids profile (total cholesterol, triglycerides, HDL, LDL) and diabetes biomarkers (insulin, glucose, HbA1c). 2. Blood tests of adiponectin (only at baseline and 48 weeks after surgery). 3. Fibroscan test for quantifying liver fibrosis by means of elastography (only at baseline and 48 weeks after surgery). 4. A blood test (FibroMax) for determining the stage and grade of liver damage (only at baseline and at 24 and 48 weeks after surgery). 5. OWLiver® test (a serum based test that can discriminate NAFLD from steatohepatitis using metabolomics) at baseline and 48 weeks after surgery.

Time frame: Baseline is defined as three weeks to one month before surgery. Different stages to compare to baseline are as following: 8-12 days and 12, 24 and 48 weeks after surgery.

Secondary Outcomes

Change of postoperative cardiovascular risk compared to baseline.

Patients will undergo brachial artery flow-mediated dilation (FMD) test (surrogate marker for endothelial function and cardiovascular risk).

Time frame: Baseline is defined as three weeks to one month before surgery. Change will be assessed 6-12 months after surgery.

Change in cholecystokinin levels before and after the surgery.

In addition, gastric cholecystokinin levels will be measured from the removed stomach tissue.

Time frame: Baseline levels of cholecystokinin at 1-2 days before surgery compared to 8-12 days after surgery.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.